SBIR Phase II: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$487,812.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
1127467
Agency Tracking Number:
1127467
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
n/a
Small Business Information
Echelon Biosciences
675 Arapeen Dr Suite 302, Salt Lake City, UT, 84108-1228
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
179151188
Principal Investigator:
Damian Madan
(801) 588-0455
dmadan@echelon-inc.com
Business Contact:
Damian Madan
(801) 588-0455
dmadan@echelon-inc.com
Research Institution:
Stub




Abstract
This Small Business Innovation Research (SBIR) Phase II project aims to further develop ATX-Red, an in vivo imaging agent that becomes fluorescent in the presence of the enzyme autotaxin. Autotaxin and its product LPA are involved in numerous biological functions that generally involve cell movement, and their dysregulation is associated with many diseases including cancer, fibroses, cardiovascular disease, and others. In Phase I ATX-Red generated highly informative images in living organisms, essentially ?lighting up? tumors. In Phase II ATX-Red metabolic stability will be improved and increased performance will be demonstrated. Then ATX-Red will be used to monitor progression and treatment of breast cancer and pulmonary fibrosis in mice. The broader impacts of this research are improvements to basic research, drug discovery, clinical diagnosis and disease treatment, with the ultimate result being an improvement to human health. ATXRed will be an indispensible tool to the many basic research fields associated with autotaxin and LPA, where questions regarding autotaxin in vivo were essentially unanswerable prior to the development of this tool. In addition to its usage in the research arena, ATX-Red will aid development of therapeutics. Currently significant efforts are underway to develop drugs targeting autotaxin pathways. ATX-Red will likely be employed in the extensive in vivo experimentation needed to develop these compounds. Human patients also stands to benefit from this research, since ATX-Red could act as a companion diagnostic for pharmaceuticals targeting diseases associated with autotaxin dysregulation. Further clinical applications might include diagnosing disease and even directing surgical resection of tumors.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government